ReviewJournal of human genetics2016
Revisited HLA and non-HLA genetics of Takayasu arteritis--where are we?
Review in Journal of human genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 78 citations in OpenAlex.
- Takayasu Arteritis in a Middle-aged Woman Following Prolonged Subsequent Fever after COVID-19 Infection: An Early Diagnosis Using Contrast-enhanced CT.Internal medicine (Tokyo, Japan) · 2026Article
- Association of genetic variants with extravascular complications and cytokine production in Takayasu arteritis: a cross-sectional study.Rheumatology advances in practice · 2026Article
- Long-read transcriptomics of a diverse human cohort reveals ancestry bias in gene annotation.Nature communications · 2025Article
- Positron Emission Tomography in Takayasu Arteritis: A Review Including Patterns of Vascular Involvement Across Modalities and Regions.Journal of clinical medicine · 2025Review
- Infliximab rather than tocilizumab for HLA-B52-positive Takayasu arteritis?Clinical rheumatology · 2024Article
- Article
- High-throughput sequencing reveals the change of TCR α chain CDR3 with Takayasu arteritis.Immunity, inflammation and disease · 2023Article
- Takayasu's Arteritis in Mexican Monozygotic Twins: Analysis of Human Leukocyte Antigens (HLA) Haplotypes.Annals of vascular diseases · 2023Article
- Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis.Arthritis research & therapy · 2023Article
- Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India.Diagnostics (Basel, Switzerland) · 2022Article
- Advances in Takayasu arteritis: An Asia Pacific perspective.Frontiers in medicine · 2022Review
- An Update on Childhood-Onset Takayasu Arteritis.Frontiers in pediatrics · 2022Review
- HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study.Arthritis research & therapy · 2021Article
- Single-Cell RNA Sequencing Revealed CD14Frontiers in cell and developmental biology · 2021Article
- Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.Current rheumatology reports · 2020Review
- [Treatment of Takayasu arteritis].Zeitschrift fur Rheumatologie · 2020Review
- Giant Cell Arteritis versus Takayasu Arteritis: An Update.Mediterranean journal of rheumatology · 2020Article
- Stroke as the initial presentation of Takayasu's arteritis: A case report.Radiology case reports · 2020Article
- Childhood-onset Takayasu Arteritis.European journal of rheumatology · 2020Article
- Pathophysiology and therapy of systemic vasculitides.EXCLI journal · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takayasu arteritis (TAK) is an immune-mediated vasculitis affecting large arteries first reported in 1908 from Japan. Case reports of familial onset of TAK from Japan and other countries indicated genetic contribution to TAK onset beyond ethnicity. Genetic studies of TAK have been performed mainly addressing the human leukocyte antigen (HLA) locus. HLA genetic studies of TAK that have previously been reported are reviewed in this manuscript. HLA-B*52:01 is associated with TAK beyond population. Many of the associations other than HLA-B*52:01 can be explained by a haplotype with HLA-B*52:01. HLA-B*67:01 is a novel susceptibility HLA-B allele to TAK confirmed in the Japanese population. Further independent associations are suggested in the HLA locus. Involvement of the 171st and 67th amino acid residues with TAK onset has been indicated. The 67th amino acid may explain the difference in susceptibility effects to TAK and Behçet's disease between HLA-B*52:01 and *51:01. HLA-B*52:01 is associated not only with TAK susceptibility but also with clinical phenotypes. Recent genome-wide association studies of TAK revealed multiple non-HLA susceptibility genes. In particular, the IL12B region seems to have a central role in TAK onset and its progression. Whether TAK and giant cell arteritis (GCA), the other vasculitis affecting large arteries, are the same disease is an interesting question to address in spite of different clinical manifestations between the two diseases. GCA is associated with HLA-DR4, which is not associated with TAK. GCA is not associated with HLA-Bw52. These two diseases seem not to share non-HLA susceptibility loci based on the recent genetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.